teneligliptin + atorvastatin

Teneligliptin + atorvastatin is a fixed-dose combination of two small molecule drugs used primarily in the management of type 2 diabetes mellitus and dyslipidemia. Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels, thereby enhancing insulin secretion and reducing glucagon secretion, which helps to lower blood glucose levels. Atorvastatin is an HMG-CoA reductase inhibitor (statin) that reduces cholesterol synthesis in the liver, leading to decreased low-density lipoprotein (LDL) cholesterol and triglycerides while increasing high-density lipoprotein (HDL) cholesterol. The combination targets both glycemic control and lipid abnormalities commonly seen in patients with type 2 diabetes, aiming to reduce cardiovascular risk by addressing hyperglycemia and dyslipidemia simultaneously[1][3][6].